These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 23059357

  • 21. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.
    Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB.
    Pediatr Infect Dis J; 2012 Jul; 31(7):745-51. PubMed ID: 22466322
    [Abstract] [Full Text] [Related]

  • 23. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S, Tagliaferri L, Daleno C, Valzano A, Picciolli I, Tel F, Prunotto G, Serra D, Galeone C, Plebani A, Principi N.
    Vaccine; 2011 Feb 11; 29(8):1677-82. PubMed ID: 21199699
    [Abstract] [Full Text] [Related]

  • 24. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers.
    de Bruijn IA, Nauta J, Gerez L, Palache AM.
    Virus Res; 2004 Jul 11; 103(1-2):139-45. PubMed ID: 15163502
    [Abstract] [Full Text] [Related]

  • 25. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
    Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ.
    Vaccine; 2012 Jan 05; 30(2):329-35. PubMed ID: 22080174
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
    Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H.
    Vaccine; 2011 Oct 19; 29(45):8049-59. PubMed ID: 21864624
    [Abstract] [Full Text] [Related]

  • 27. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients.
    Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Mühlemann K.
    Clin Infect Dis; 2009 May 15; 48(10):1402-12. PubMed ID: 19361304
    [Abstract] [Full Text] [Related]

  • 28. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ.
    Pediatr Infect Dis J; 2012 Jul 15; 31(7):e92-8. PubMed ID: 22481427
    [Abstract] [Full Text] [Related]

  • 29. Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
    Künzi V, Dornseiff M, Horwath J, Hartmann K.
    Vaccine; 2009 Feb 18; 27(8):1261-5. PubMed ID: 19114080
    [Abstract] [Full Text] [Related]

  • 30. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 31. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.
    Loew-Baselli A, Pavlova BG, Fritsch S, Poellabauer EM, Draxler W, Kistner O, Behre U, Angermayr R, Neugebauer J, Kirsten K, Förster-Waldl E, Koellges R, Ehrlich HJ, Barrett PN.
    Vaccine; 2012 Sep 07; 30(41):5956-66. PubMed ID: 22846396
    [Abstract] [Full Text] [Related]

  • 32. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.
    Vaccine; 2011 Nov 15; 29(49):9209-13. PubMed ID: 21974995
    [Abstract] [Full Text] [Related]

  • 33. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 15; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 34. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
    Phongsamart W, Sirisanthana V, Wittawatmongkol O, Maleesatharn A, Sudjaritruk T, Chearskul P, Aurpibul L, Sirisanthana T, Chokephaibulkit K.
    Vaccine; 2011 Nov 03; 29(47):8705-11. PubMed ID: 21893147
    [Abstract] [Full Text] [Related]

  • 35. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ.
    Vaccine; 2010 Aug 31; 28(38):6221-7. PubMed ID: 20638454
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA.
    Vaccine; 2012 Jan 20; 30(5):879-85. PubMed ID: 22155630
    [Abstract] [Full Text] [Related]

  • 37. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.
    Vaccine; 2008 Nov 25; 26(50):6383-91. PubMed ID: 18801398
    [Abstract] [Full Text] [Related]

  • 38. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
    Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, Tchidjou HK, Aquilani A, Cotugno N, Alghisi F, Lucidi V, Rossi P, Douagi I.
    Biologicals; 2012 Mar 25; 40(2):134-9. PubMed ID: 22261282
    [Abstract] [Full Text] [Related]

  • 39. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.
    Vaccine; 2012 Jul 06; 30(32):4820-7. PubMed ID: 22626675
    [Abstract] [Full Text] [Related]

  • 40. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy.
    Esposito S, Gasparini C, Martelli A, Zenga A, Tremolati E, Varin E, Marseglia GL, Fiocchi A, Principi N.
    Vaccine; 2008 Aug 26; 26(36):4664-8. PubMed ID: 18639601
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.